US2018327745A1PendingUtilityA1
Methods of controlling cell fate and consequences for disease
Assignee: MASSACHUSETTS GEN HOSPITALPriority: Aug 26, 2014Filed: Jul 24, 2018Published: Nov 15, 2018
Est. expiryAug 26, 2034(~8.1 yrs left)· nominal 20-yr term from priority
C12N 5/0696C12N 15/113C12N 2506/30C12N 2501/606C12N 2501/602C12N 2501/998C12N 2310/141C12N 2320/12C12N 2310/14C12N 2501/60C12N 2501/603C12N 2501/604C12N 2506/1307C12N 2310/531C12N 2330/31
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are methods for performing cellular reprogramming that include treatment of somatic cells with an inhibitor of CAF-1, Sumo2, Nutd21, or combinations thereof prior to or during a reprogramming procedure. Such inhibitors can improve both the speed and efficiency of cellular reprogramming. Inhibitors of the CAF-1 complex can also be used in the treatment of cancer.
Claims
exact text as granted — not AI-modified1 . A method of inducing differentiation of a cancer cell or cancer stem cell in vivo, the method comprising: administering an inhibitor of the CAF-1 complex to a subject having, or suspected of having cancer, thereby inducing differentiation of the cancer cell or cancer stem cell in vivo.
2 . The method of claim 1 , wherein the cancer comprises leukemia.
3 . The method of claim 1 , wherein the inhibitor comprises an RNA interference molecule or an antibody.
4 . The method of claim 3 , wherein the RNA interference molecule comprises an siRNA or an shRNA.Join the waitlist — get patent alerts
Track US2018327745A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.